A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called JNJ-88260237 to see if it is safe and well-tolerated when taken by healthy people in a single dose.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the study is for healthy participants, it might imply that you should not be on any regular medication. Please check with the study coordinators for confirmation.
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single oral dose of JNJ-88260237 or placebo
Follow-up
Participants are monitored for safety and pharmacokinetics after treatment
What Are the Treatments Tested in This Trial?
Interventions
- JNJ-88260237
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University